Katrin Preller received her M.Sc. (Neuropsychology and Clinical Psychology) from University of Konstanz, Germany. She joined the University of Zurich where she investigated the neurobiological long-term effects of cocaine, MDMA, and heroin use. After completing her PhD, she investigated the mechanistic effects of psychedelics at the Neuropsychopharmacology and Brain Imaging Lab. She received a SNSF PostDoc mobility fellowship and worked at the Wellcome Trust Centre for Neuroimaging, UCL, London, and Yale University, New Haven. Subsequently, she was appointed as Group Leader at the University of Zurich, and held a position as Visiting Assistant Professor at Yale University. Her academic work focuses on the clinical and mechanistic effects of novel therapies in neuropsychiatry. In 2020 she joined Fa-Hoffmann La Roche as Biomarker and Experimental Medicine Leader and subsequently Boehringer-Ingelheim as Principal Clinical Biomarker Lead CNS. Katrin Preller has published over 80 research papers and has been awarded several research prices.